Logo image of CNVY

Convey Health Solutions Holdings Inc (CNVY) Stock Fundamental Analysis

NYSE:CNVY - New York Stock Exchange, Inc. - US21258C1080 - Common Stock - Currency: USD

10.51  -0.05 (-0.47%)

After market: 10.51 0 (0%)

Fundamental Rating

2

Taking everything into account, CNVY scores 2 out of 10 in our fundamental rating. CNVY was compared to 39 industry peers in the Health Care Technology industry. CNVY has a bad profitability rating. Also its financial health evaluation is rather negative. CNVY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CNVY had negative earnings in the past year.
CNVY Yearly Net Income VS EBIT VS OCF VS FCFCNVY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 0 10M -10M 20M 30M

1.2 Ratios

Industry RankSector Rank
ROA -0.76%
ROE N/A
ROIC 1.87%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNVY Yearly ROA, ROE, ROICCNVY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 0 1 -1 2 -2

1.3 Margins

Industry RankSector Rank
OM 5.47%
PM (TTM) -1.9%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNVY Yearly Profit, Operating, Gross MarginsCNVY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 0 10 20 30 40

More info and screens

2

2. Health

2.1 Basic Checks

CNVY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for CNVY has been increased compared to 1 year ago.
Compared to 1 year ago, CNVY has an improved debt to assets ratio.
CNVY Yearly Shares OutstandingCNVY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 20M 40M 60M
CNVY Yearly Total Debt VS Total AssetsCNVY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.68, we must say that CNVY is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 0.50 indicates that CNVY is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF N/A
Altman-Z 1.68
ROIC/WACC0.18
WACC10.35%
CNVY Yearly LT Debt VS Equity VS FCFCNVY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 100M 200M 300M 400M 500M

2.3 Liquidity

CNVY has a Current Ratio of 2.20. This indicates that CNVY is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 1.60 indicates that CNVY should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 1.6
CNVY Yearly Current Assets VS Current LiabilitesCNVY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.74% over the past year.
CNVY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.45%.
Measured over the past years, CNVY shows a very strong growth in Revenue. The Revenue has been growing by 23.55% on average per year.
EPS 1Y (TTM)28.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)16.45%
Revenue growth 3Y23.55%
Revenue growth 5YN/A
Sales Q2Q%19.31%

3.2 Future

CNVY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 91.65% yearly.
Based on estimates for the next years, CNVY will show a quite strong growth in Revenue. The Revenue will grow by 15.76% on average per year.
EPS Next Y406.25%
EPS Next 2Y171.28%
EPS Next 3Y119.84%
EPS Next 5Y91.65%
Revenue Next Year19.05%
Revenue Next 2Y17.57%
Revenue Next 3Y16.68%
Revenue Next 5Y15.76%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CNVY Yearly Revenue VS EstimatesCNVY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
CNVY Yearly EPS VS EstimatesCNVY Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CNVY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 24.03, CNVY is valued on the expensive side.
The average S&P500 Price/Forward Earnings ratio is at 22.68. CNVY is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 24.03
CNVY Price Earnings VS Forward Price EarningsCNVY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 19.33
CNVY Per share dataCNVY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

CNVY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CNVY's earnings are expected to grow with 119.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y171.28%
EPS Next 3Y119.84%

More info and screens

0

5. Dividend

5.1 Amount

CNVY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Convey Health Solutions Holdings Inc

NYSE:CNVY (10/6/2022, 8:04:00 PM)

After market: 10.51 0 (0%)

10.51

-0.05 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-12 2022-08-12/amc
Earnings (Next)11-09 2022-11-09/amc
Inst Owners0.11%
Inst Owner Change0%
Ins Owners1.08%
Ins Owner Change0%
Market Cap769.56M
Analysts48.89
Price Target11.22 (6.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 24.03
P/S 2.1
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB N/A
EV/EBITDA 19.33
EPS(TTM)-0.1
EYN/A
EPS(NY)0.44
Fwd EY4.16%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS5
BVpS7.25
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.76%
ROE N/A
ROCE N/A
ROIC 1.87%
ROICexc N/A
ROICexgc 12.86%
OM 5.47%
PM (TTM) -1.9%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 1.6
Altman-Z 1.68
F-Score6
WACC10.35%
ROIC/WACC0.18
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y406.25%
EPS Next 2Y171.28%
EPS Next 3Y119.84%
EPS Next 5Y91.65%
Revenue 1Y (TTM)16.45%
Revenue growth 3Y23.55%
Revenue growth 5YN/A
Sales Q2Q%19.31%
Revenue Next Year19.05%
Revenue Next 2Y17.57%
Revenue Next 3Y16.68%
Revenue Next 5Y15.76%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A